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Objective: As a receptor for both vascular endothelial growth factors and semaphorin, neuropilin-1 (NRP-1) is
reported to be up-regulated in cells of several cancers. However, its roles in human nasopharyngeal carcinoma
(NPC) are still unclear. Therefore, the goal of this study was to investigate the expression pattern of NRP-1 in NPC
tissues, to clarify the clinical significance of NRP-1 expression in NPC as well as the potential prognostic implication
of NRP-1 expression.
Methods: Immunohistochemistry was performed to detect the expression of NRP-1 in tumor tissue samples from
266 NPC patients. The association of NRP-1 protein expression with the clinicopathological characteristics and the
prognosis of NPC were subsequently assessed.
Results: Immunohistochemical analysis showed that 176 of 266 (66.17%) paraffin-embedded archival NPC biopsies
showed high expression of NRP-1, but no non-cancerous nasopharyngeal specimens showed positive expression
of NRP-1. In addition, high NRP-1 expression was significantly associated with advanced clinical stage (P = 0.02),
positive recurrence (P = 0.001) and metastasis status (P = 0.001) of NPC. Moreover, the NPC patients with higher
NRP-1 expression had shorter overall survival, whereas patients with lower NRP-1 expression had better survival
(P < 0.001). Furthermore, the multivariate analysis indicated that the overexpression of NRP-1 protein was an
independent prognostic factor for overall survival (P = 0.001) in NPC patients.
Conclusion: These findings suggest for the first time that NRP-1 upregulation may be a novel biomarker for
the prediction of advanced tumor progression and unfavorable prognosis in NPC patients who may benefit
from alternative treatment strategy and targeted treatment.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1507827881105018.
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Nasopharyngeal carcinoma (NPC), as an Epstein-Barr virus
(EBV)-related cancer, is one of the most common malig-
nant diseases with a high prevalence in Southern China,
Southeast Asia and North Africa [1]. NPC accounts for
80,000 new cases and 50,000 deaths annually in the world
[2]. Different from other head and neck cancers, NPC has
a high metastatic potential. The majority (75 ~ 90%) of
newly diagnosed NPC patients have loco-regionally ad-
vanced disease, commonly with cervical nodal metastases* Correspondence: xuyuhayy@163.com
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reproduction in any medium, provided the or[3]. Although radiotherapy alone or combined with chemo-
therapy is relatively successful for curing the cancer, a sub-
stantial proportion of patients do not benefit from these
conventional treatments but show loco-regional recur-
rence, and regional lymph node and distant metastasis are
the two major reasons resulted in failure of treatment in
clinical practice, which suggest that NPC is no longer a
problematic disease from a loco-regional control stand-
point and research priorities should lie in the develop-
ment of innovative strategies in order to prevent distant
relapse, prolonging remission in those with metastatic
disease and minimizing treatment toxicities [4]. The etio-
logic factors associated with NPC include genetic suscep-
tibility, EBV infection, and other environmental factors [5].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Association of NRP-1 expression with
clinicopathologic parameters of nasopharyngeal
carcinoma patients
Parameters N NRP-1 expression (n, %) P
High Low
Age
< 48 100 63 (63.00) 37 (37.00) NS
≥ 48 166 113 (68.07) 53 (31.93)
Gender
Male 166 106 (63.86) 60 (36.14) NS
Female 100 70 (70.00) 30 (30.00)
Clinical stage
I ~ II 68 30 (44.12) 38 (55.88) 0.02
III ~ IV 198 146 (73.74) 52 (27.26)
T-stage
T1 ~ T2 90 55 (61.11) 35 (38.89) NS
T3 ~ T4 176 121 (68.75) 55 (31.25)
N-stage
N0 78 50 (64.10) 28 (35.90) NS
N1 ~ N3 188 126 (67.02) 62 (32.98)
WHO histological type
II 76 50 (65.79) 26 (34.21) NS
III 190 136 (71.58) 54 (28.42)
Recurrence
No 196 116 (59.18) 80 (40.92) 0.001
Yes 70 60 (85.71) 10 (14.29)
Metastasis
No 211 128 (60.66) 63 (39.34) 0.001
Yes 55 48 (87.27) 7 (12.73)
‘NS’ refers to the difference without statistical significance.
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on clinical findings would include Nasal Polyps, Non-
Hodgkin Lymphoma, and Rhabdomyosarcoma. Especially,
extranodal NK/T-cell lymphoma, nasal type (ENKTL),
a distinct clinical pathological entity of non-Hodgkin’s
lymphoma, is closely associated with EBV infection [6],
which is similar to NPC. Since the exact molecular mech-
anism of the development and progression of NPC remains
poorly understood, it is of great significance to identify po-
tential early diagnostic markers as well as novel therapeutic
targets.
Neuropilins (NRPs) are transmembrane glycoprotein
receptors which are capable of binding two disparate li-
gands, class 3 semaphorins (Sema) and vascular endothelial
growth factors (VEGF) [7]. NRPs have been demonstrated
to play an important role in various biological processes,
including axonal guidance, angiogenesis, tumorigenesis,
and the immunologic response [8]. To data, two NRP
members, NRP-1 and NRP-2, have been identified. NRP-1
is a 130- to 140-kDa single spanning transmembrane
glycoprotein originally identified as a receptor for class III
semaphorins (SEMA3s) mediating neuronal guidance and
axonal growth [9]. Then, it was subsequently found to bind
to VEGF which is a critical pro-angiogenic factor that in-
duces proliferation and migration of endothelial cells to
tumor vasculature. NRP-1 is reported to be up-regulated
in cells of several cancers such as glioma [10], prostate car-
cinoma [11], breast cancer [12], gastric cancer [13], pancre-
atic carcinoma [14], colon cancer [15] and acute myeloid
leukemia [16]. Recent studies have indicated that the
overexpression of NRP-1 may enhance tumor angiogenesis
and tumor growth in vivo. In contrast, the inhibition of
NRP-1 may suppress cell survival and migration [17].
However, it roles in human nasopharyngeal carcinoma
(NPC) are still unclear. Therefore, the goal of this study
was to investigate the expression pattern of NRP-1 in NPC
tissues, to clarify the clinical significance of NRP-1 expres-
sion in NPC as well as the potential prognostic implication
of NRP-1 expression.
Materials and methods
Patients and tissue samples
The study was approved by the Research Ethics Com-
mittee of Ministry of Public Health of China. Informed
consent was obtained from all of the patients.
Two hundred and sixty-six archival formalin-fixed,
paraffin-embedded NPC specimens and 100 non-
cancerous nasopharyngeal specimens were obtained from
Huai’an First People’s Hospital, Nanjing Medical University
during 1996 ~ 2006. In the 266 NPC patients, there were
166 male and 100 female with age ranging from 16 to
80 years (median, 48 years). None of the patients recruited
in this study had chemotherapy or radiotherapy before the
surgery. Clinical information was obtained by reviewingthe medical records on radiographic images, by telephone
or written correspondence, and by review of death certifi-
cate. All specimens had confirmed pathological diagnosis
and were staged according to the 1992 NPC staging system
of China. Clinical characteristics of these patients are sum-
marized in Table 1.
For the analysis of survival and follow-up, the date of
surgery was used to represent the beginning of the
follow-up period. All the patients who died from dis-
eases other than NPC or from unexpected events were
excluded from the case collection. Follow-ups were termi-
nated until March 8, 2012. The median follow-up period
was 46 months (range, 3–126 months). Treatment modal-
ities after relapse were given according to a uniform guide-
line as described.
Immunohistochemistry analysis
Expression pattern of NRP-1 protein in 266 NPC speci-
mens and 100 non-cancerous nasopharyngeal specimens
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all tissue specimens were retrieved and cut into 4-μm sec-
tions and mounted on pre-coated slides. After depara-
ffinizing in xylene and washing in a graded series of
ethanol, Sections were submerged into EDTA antigenic
retrieval buffer and microwaved for antigenic retrieval.
The slides were incubated with the primary antibody
against NRP-1 (rabbit polyclonal anti-human NRP-1,
1:100 dilutions, Zymed No. 34–7300, San Francisco,
CA, USA). All incubations with primary antibody were car-
ried out overnight at 4°C. After washing in TBS (Sigma,
Munich, Germany), the tissue sections were treated with
biotinylated anti-rabbit secondary antibody (Zymed, San
Francisco, CA), followed by further incubation with strep-
tavidinhorseradish peroxidase complex (Zymed). The tis-
sue sections were immersed in 3-amino-9-ethyl carbazole
and counterstained with 10% Mayer’s hematoxylin, dehy-
drated, and mounted in Crystal Mount. In each im-
munohistochemistry run, non-cancerous nasopharyngeal
specimens were used as control tissues and omission of the
primary antibody served as negative control. All tissue
samples were stained at one time.
Following a hematoxylin counterstaining, immunostain-
ing was scored by two independent observers, who were
blinded to the clinicopathological parameters and clinical
outcomes of the patients. The scores of the two observers
were compared and any discrepant scores were trained
through re-examining the stainings by both pathologists to
achieve a consensus score. The number of positive-staining
cells showing immunoreactivity on the cell membrane
and/or cytoplasm (for NRP-1) in ten representative micro-
scopic fields was counted and the percentage of positive
cells was calculated. The frequency of NRP-1 immunoreac-
tivity in tissue sections was evaluated as negative (0) when
no positive cells were observed within the tumor, weak
(1) when < 30% of the tumor cells were positive, moderate
(2) when 30% to 60% of the tumor cells were positive, and
strong (3) when >60% of tumor cells were positive. The in-
tensity of staining was evaluated as 0, 1, 2, and 3 for no
staining, weak staining, medium staining, and strong stain-
ing, respectively. Immunohistochemical scores were deter-
mined as the sum of the frequency and intensity score for
tumor cells. Cutoff values for immunohistochemical scores
of NRP-1 protein were chosen on the basis of a measure of
heterogeneity with the log-rank test statistic with respect
to overall survival. An optimal cutoff value was identified.
An immunohistochemical score of ≥ 4 was used to classify
tumors with high expression, and an immunohistochemi-
cal score < 4 was used to classify tumors with low expres-
sion of NRP-1 antigen.
Statistical analysis
The software of SPSS version 16.0 for Windows (SPSS
Inc, IL, USA) and SAS 9.1 (SAS Institute, Cary, NC) wasused for statistical analysis. Continuous variables were
expressed as X  s. Associations between the expres-
sion of NRP-1 and clinicopathological parameters were
assessed using a Chi-Square test. Survival curves were plot-
ted by Kaplan-Meier analysis and compared by the log-
rank test. Cox regression analysis was performed to assess
the significance of various variables for survival. Differ-
ences were considered statistically significant when p was
less than 0.05.
Results
Upregulation of NRP-1 in human NPCs
Expression and subcellular localization of NRP-1 protein
was detected by immunohistochemistry in 266 NPC speci-
mens and 100 non-cancerous nasopharyngeal specimens.
The coefficient of variation of interobserver reproducibility
was 9.62% for NRP-1 expression scoring, with no sig-
nificant differences between the two observers (paired
t-test, P = 0.82). As shown in Figure 1, the cell membrane
and/or cytoplasm of most tumor cells in the NPC sec-
tions stained intensely with NRP-1 antibody (Figure 1A),
while negative immunostainings were observed in all
non-cancerous nasopharyngeal tissues (Figure 1B). High
NRP-1 expression was observed in tumor cells of 66.17%
(176/266) NPCs.
Association of NRP-1 protein expression with the
clinicopathological characteristics of human NPCs
Table 1 summarized the association of NRP-1 protein
expression in 266 NPCs detected by immunohistochemi-
cal staining. High NRP-1 expression is closely associated
with advanced clinical stage of NPC patients (P = 0.02).
In addition, there was a significant difference of NRP-1
expression in patients categorized according to recur-
rence status (P = 0.001). The expression levels of NRP-1
protein in NPC patients with positive recurrence were
significantly higher than those without recurrence. More-
over, positive metastasis also correlated with higher NRP-1
expression (P = 0.001). No significant association between
NRP-1 expression and age, gender, T-stage, N-stage or
WHO histological type was observed (Table 1).
Association of NRP-1 protein expression with the prognosis
of human NPCs
The association of NRP-1 protein expression with the
prognosis of human NPCs was also evaluated. The 5-
year overall survival rate of the cohort of 266 NPC
patients was 66.17% (196/266). Kaplan-Meier analysis
and the log-rank test were used to calculate the effect of
classic clinicopathologic characteristics (including age,
gender, clinical stage, T-stage, N-stage, WHO histologic
type, recurrence and metastasis) and NRP-1 expression on
survival. The log-rank test showed that the low NRP-1
Figure 1 Immunohistochemical staining of NRP-1 protein in tumor cells of nasopharyngeal carcinoma (NPC, A) and non-cancerous
nasopharyngeal tissues (B; Original magnification × 400). Intense staining of NRP-1 is seen in the cell membrane and/or cytoplasm of
tumors cells and is intensive in NPC tissues (A). In contrast, negative immunostainings of NRP-1 (B) was observed in non-cancerous
nasopharyngeal tissues.
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NRP-1 expression group had shorter survival (P < 0.001,
Figure 2). In addition, clinical stage, recurrence and me-
tastasis were also significantly correlated with survival in
Kaplan-Meier analysis and log-rank test (for clinical stage,
P = 0.002; for recurrence and metastasis, P = 0.001, Table 2).
Moreover,we did multivariate survival analysis, which in-
cluded NRP-1 expression level, clinical stage, recurrence
and metastasis, to determine if NRP-1 expression level
is an independent prognostic factor of outcomes. In this
analysis, clinical stage (HR = 6.193, 95% CI: 1.011-13.392,
P = 0.006), recurrence (HR = 6.928, 95% CI: 0.922-13.556,
P = 0.005), metastasis (HR = 6.893, 95% CI: 1.023-13.528,Figure 2 Kaplan-Meier survival plots of NRP-1 protein expression.
Kaplan-Meier survival analysis revealed that the NPC patients
overexpressing NRP-1 protein exhibited markedly poorer overall
survival (P < 0.001).P = 0.005), and NRP-1 expression (HR = 8.631, 95% CI:
1.392-18.288, P = 0.001) were recognized as independ-
ent prognostic factors for NPC patients (Table 3).
Discussion
NPC is a malignancy with significant geographic and ra-
cial distributions worldwide. Carcinogenesis of NPC is a
multistep process with morphological progression in-
volving multiple genetic and epigenetic events. There-
fore, it is of great significance to identify the molecular
and biological changes that occur during carcinogenesis
and progression, in order to facilitate the investigation of
the pathology of the disease and generate new prognos-
tic markers to more accurately screen patients who are
at the great risk of relapse after their primary treatment.
In the present study, we analyzed the expression of
NRP-1 with the clinicopathologic parameters in NPC pa-
tients. We observed the overexpression of NRP-1 in NPC
tissues to be associated with advanced clinical stage, posi-
tive recurrence and metastasis status, and poor prognosis,
suggesting that the overexpression of NRP-1 may be a
novel independent marker for progression and prognosis
in NPC patients. To the best of our knowledge, this is the
first research on the role of NRP-1 expression in a large co-
hort of NPC patients.
NRP-1 is a single-spanning transmembrane glycopro-
tein with a large extracellular domain and a short cyto-
plasmic tail [18]. It has been known to have an important
role in angiogenesis as a VEGFR and is involved in neur-
onal guidance during embryogenesis [19]. According to
the experiments in vivo, the overexpression of NRP-1 in
a transgenic mouse model may increase capillary and
blood vessel formation leading to hemorrhage, whereas
functional inactivation of NRP-1 in mice may result in
embryonic lethality with multiple vascular abnormalities,
Table 2 Univariate analysis of different prognostic varibles in 266 nasopharyngeal carcinoma patients
Variables Subset Hazard ratio (HR) 95% confidence interval [CI] P
Patient gender Male vs. Female 1.987 0.608 ~ 4.092 NS
Patient age < 48 vs. ≥ 48 1.566 0.465 ~ 3.853 NS
Clinical stage I ~ II vs. III ~ IV 7.382 1.031-16.613 0.002
T-stage T1 ~ T2 vs. T3 ~ T4 2.380 0.738 ~ 5.046 NS
N-stage N0 vs N1 ~ N3 1.778 0.732 ~ 4.028 NS
WHO histological type II vs. III 1.458 0.689 ~ 3.076 NS
Recurrence No vs. Yes 8.892 1.021-18.656 0.001
Metastasis No vs. Yes 8.788 1.042-19.052 0.001
NRP-1 Low vs. High 16.926 1.833-38.132 < 0.001
‘NS’ refers to the difference without statistical significance.
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sel size and abnormally formed dorsal aorta [20]. These
findings suggest that NRP-1 may be a key regulator of de-
velopmental angiogenesis. Pathologically, the upregulation
of NRP-1 has been found in a variety of tumor cells and
has been demonstrated to be involved in tumorigenesis
and tumor progression. For example, Meyerson et al. [21]
reported that NRP-1 was overexpressed in precursor B-cell
acute lymphoblastic leukemia samples compared with nor-
mal B-cell progenitors, allowing for its potential use as a
marker for the detection of minimal residual disease; Li
et al. [22] demonstrated that NRP-1 was overexpressed in
glioblastoma and may be an attractive candidate as a thera-
peutic target for this disease; Xu et al. [23] indicated that
NRP-1 may be able to promote the growth of hepatocellu-
lar carcinoma in vitro and in vivo, and therefore may be
considered as a novel therapeutic target for this carcinoma;
Hansel et al. [24] found the increased expression of NRP-1
in gastrointestinal adenocarcinomas and in a subset of
high-grade precursor lesions, which appears to parallel in-
vasive behavior and may therefore be used as a potential
marker for cancer aggressiveness; Baba et al. [25] reported
that the enhanced expression of NRP-1 may be not only
associated with oncogenesis, but also with ovarian cancer
malignancy, and this molecule may be a targeting candi-
date for the treatment of ovarian malignancies; Stephenson
et al. [26] also suggested that the upregulation of NRP-1
may be involved in the induction of local invasiveness ofTable 3 Multivariate cox regression analysis of different







Clinical stage I ~ II vs. III ~ IV 6.193 1.011-13.392 0.006
Recurrence No vs. Yes 6.928 0.922-13.556 0.005
Metastasis No vs. Yes 6.893 1.023-13.528 0.005
NRP-1 Low vs. High 8.631 1.392-18.288 0.001neoplasia and angiogenesis and have direct relevance to
the progression of breast cancer. In line with these previ-
ous studies, our immunohistochemistry analysis also found
the overexpression of NRP-1 in NPC tissues compared
with non-cancerous nasopharyngeal tissues. More import-
antly, the upregulation of NRP-1 was significantly associ-
ated with the advanced clinical stage, positive recurrence
and metastasis status of NPC patients. It is worth noting
that overexpression of NRP-1 protein was found to be an
indicator of poor prognosis in NPC patients, and NRP-1
expression, clinical stage, recurrence and metastasis were
independent predictors of NPC. However, in colon cancer,
Kamiya et al. [27] found that the gene expression levels of
NRP-1 were significantly decreased compared to those in
the extra-neoplastic tissues, and the preserved NRP-1 ex-
pression provides colon cancer patients with a better prog-
nosis. These results suggest that NRP-1 has cancer-type
dependent expression patterns in various cancers and the
abnormal expression of NPR-1 may play important roles in
tumor progression and tumor prognosis.
In conclusion, our data show for the first time that
NRP-1 upregulation may be a novel biomarker for the
prediction of advanced tumor progression and unfavor-
able prognosis in NPC patients who may benefit from
alternative treatment strategy. These findings support
the hypothesis of an important role for NRP-1 in aggres-
sive progression of NPC, so that targeting of NRP-1 could
constitute a novel strategy in the treatment of advanced
NPC. Future research should address this interesting issue
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